Israel Englander’s Impact BioMedical IBO Stock Holding History

Israel Englander’s Portfolio IBO Stock Details IBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-137,823	Closed	-$69.6K	–	6524
2025 Q4	$69.6K	Buy	+137,823	New	+$72.9K	﹤0.01%	5689

Other funds holding IBO

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Global Advisers Malvern, Pennsylvania $215B AUM

MAC

Mason & Associates (California) Los Angeles, California $619M AUM 29.44% 1-Year Est. Return

Israel Englander's IBO Position: Q1 2026 in Review

Israel Englander sold out of Impact BioMedical (IBO) in Q1 2026, closing a stake of 137,823 shares — an estimated $69.6K sold.

Israel Englander first reported a position in IBO in Q4 2025 and held it in 1 quarter. The position peaked at $69.6K in Q4 2025. 20 funds tracked by Wall St. Rank hold IBO as of Q1 2026.

Israel Englander reported no remaining Impact BioMedical position as of Q1 2026 after selling out during the quarter.
Israel Englander sold 137,823 Impact BioMedical shares in Q1 2026, an estimated $69.6K.
Israel Englander first reported a position in Impact BioMedical in Q4 2025 and held it in 1 quarter.
Israel Englander's Impact BioMedical position peaked at $69.6K in Q4 2025.
20 funds tracked by Wall St. Rank held Impact BioMedical as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.